[Do thrombolytic agents prevent postphlebitis thromboembolism?].
D000990:Antithrombin III / Q000032:analysis; D005340:Fibrinogen / Q000032:analysis; D005342:Fibrinolysis / Q000187:drug effects; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D006801:Humans; D010958:Plasminogen / Q000032:analysis; D013300:Streptokinase / Q000627:therapeutic use*; D013918:Thrombin Time; D013924:Thrombophlebitis / Q000188:drug therapy*; D013997:Time Factors; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*; D000515:alpha 1-Antitrypsin / Q000032:analysis
D005343:Fibrinolytic Agents; D000515:alpha 1-Antitrypsin; D000990:Antithrombin III; D005340:Fibrinogen; D010958:Plasminogen; D013300:Streptokinase; D014568:Urokinase-Type Plasminogen Activator
Les thrombolytiques préviennent-ils la maladie thromboembolique postphlébitique?